Registry for patients with moderate to severe allergic diseases
Official title: Atopy Network - Comprehensive Allergy Centers: Medical Care of Patients With Moderate to Severe Allergic Diseases
Run by Charite University, Berlin, Germany · NCT05334940 · Data updated 2026-11-12
This study is collecting information from people with moderate to severe allergic diseases to see how well different treatments work and how they affect their daily lives.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin) |
| Status | Recruiting |
| Started | December 8, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT05334940 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 6 and older with moderate to severe atopic disorders who are set to receive biologic systemic therapy and have at least one additional atopic condition.
✕Probably not a fit
Patients with fewer than two atopic disorders or those who are non-compliant, pregnant, or breastfeeding may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Atopy Registry aims to collect standardized data on patients with atopic disorders to evaluate the efficacy, tolerability, and safety of systemic therapies. It focuses on patients suffering from multiple atopic conditions, such as food allergies, atopic dermatitis, and asthma, to understand their medical care and quality of life. The study will also analyze biomaterials to explore potential correlations between immunological factors and the clinical presentation of these disorders. This long-term observational study seeks to establish a comprehensive registry across Germany for better management of atopic diseases.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and enhanced quality of life for patients with atopic disorders.
How similar studies have gone: Other studies have shown success in establishing registries for chronic conditions, suggesting that this approach could yield valuable insights into atopic disorders as well.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients are at least 6 years old * patients with a proven moderate to severe atopic disorder who are planned to receive a biologic systemic therapy * at least one additional proven atopic disorder Exclusion Criteria: * \<2 atopic disorders * poor compliance * pregnancy or breastfeeding
Where it's running
-
Charité - Universitätsmedizin Berlin
Berlin, Germany Recruiting
Study contacts
- Study coordinator: Margitta Worm, Prof.
- Email: margitta.worm@charite.de
- Phone: +49 30 450 518105
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How to talk about vaccines: does different communication help people decide to get vaccinated?
This online randomized trial tests whether specific communication formats can improve knowledge and willingness to get vaccinated for TBE (Germany) or yellow fever (Colombia).
-
AI-generated treatment recommendations for precision oncology
A non-interventional study tests whether AI-generated treatment options for advanced solid tumors align with what doctors would personally recommend.
-
DHEA add-on to standard antidepressants for treatment-resistant depression
This trial tests whether adding 100 mg/day of DHEA to patients’ current antidepressant treatment helps people with treatment-resistant depression feel better.
-
Context-adapted quality indicators for early sepsis care in Sub-Saharan Africa
A group of sepsis experts in Sub-Saharan Africa will participate in a series of online surveys and feedback meetings to agree on practical quality indicators for early sepsis care.
-
TNPO2-related disorders registry
This international registry tests how TNPO2 gene variants relate to neurodevelopmental issues by collecting medical, genetic, and developmental data from people with pathogenic TNPO2 variants.
-
International TRPM3 Disorder Registry
This registry tests how TRPM3-associated disorders progress by collecting and comparing patient data over time to learn about treatments and quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.